Business
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
– Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential first-
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"– Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax –\n– Company on track for two potential first- and best-in-class product launches in 2024 –\nWALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons.\n\n\"Steven Closter is an accomplished leader with a proven track record of building commercial teams, leading successful product launches and delivering growth across a broad range of therapeutic areas,\" said Michael A. Metzger, Chief Executive Officer. \"He has the right experience and capabilities to lead our growing and talented commercial organization as we work toward a successful transition to a fully integrated commercial business. We are thrilled to welcome him to the team and look forward to his contributions.\"\nMr. Closter brings to Syndax over 30 years of commercial experience, which included the oversight of over a dozen product launches and indication expansions. Prior to joining Syndax, he served in various roles at Sunovion Pharmaceuticals, which was consolidated into Sumitomo Pharma America in 2023, ultimately serving as Vice President, Brand Strategy and Launch Excellence. At Sunovion, he was responsible for global pre-commercialization, launch, marketing, sales, and market access strategies for products across neurology, psychiatry, and primary care therapeutics. Before Sumitomo, Mr. Closter spent nearly 20 years in senior marketing and commercial roles at Forest Laboratories, then Allergan, most recently serving as Vice President, Marketing, where he held responsibility for marketing products covering oncology, hospital-based anti-infectives, CNS, cardiovascular and other therapeutic areas. He holds a Bachelor of Science in Business from Cornell University and a Master of Business Administration from the NYU Stern School of Business.\n\"I have dedicated my career to strategically delivering novel medicines to patients facing a wide range of seriou...